Seeking Alpha

Analysts come out bullish on Bind Therapeutics

  • Analysts are weighing in on recently public Bind Therapeutics (BIND -1%), whose most advanced drug candidate is BIND-014, a PSMA targeting Accurin containing docetaxel.
  • Credit Suisse starts the shares at Outperform. Price target is $21.
  • Cowen initiates at Outperform with a $30 price target.
  • Stifel starts BIND at Buy. Price target is $20.
  • JMP initiates at Market Outperform. Price target is $30.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|